Repositorio Dspace

Listar por autor "Lacasta, Adelaida"

Listar por autor "Lacasta, Adelaida"

Ordenar por:Orden:Resultados:

  • Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib 
    Jiménez-Fonseca, Paula; Martín, Miguel-Navarro; Carmona-Bayonas, Alberto; Calvo, Alfonso; Fernández-Mateos, Javier; Redrado, Miriam; Capdevila, Jaume; Martínez-Lago, Nieves; Lacasta, Adelaida; Muñarriz, Javier; Segura, Ángel; Fuster, Josep; Barón, Francisco; Llanos, Marta; Serrano, Raquel; Castillo, Alfredo; Cruz-Hernández, Juan-Jesús; Grande, Enrique (IMPACT JOURNALS LLC, 2018-12-11)
    Several circulating biomarkers and single nucleotide polymorphisms (SNPs) have been correlated with efficacy and tolerability to antiangiogenic agents. These associations remain unexplored in well-differentiated, metastatic ...
  • Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study 
    Carmona-Bayonas, Alberto; Jiménez-Fonseca, Paula; Lamarca, Ángela; Barriuso, Jorge; Castaño, Ángel; Benavent, Marta; Alonso, Vicente; Riesco-Martínez, María-del-Carmen; Alonso-Gordoa, Teresa; Custodio, Ana; Sánchez-Cánovas, Manuel; Hernando-Cubero, Jorge; López, Carlos; Lacasta, Adelaida; Fernández-Montes, Ana; Marazuela, Mónica; Crespo, Guillermo; Escudero, Pilar; Díaz, José-Ángel; Feliciangeli, Eduardo; Gallego, Javier; Llanos, Marta; Segura, Ángel; Vilardell, Felip; Percovich, Juan; Grande, Enrique; Capdevila, Jaume; Valle, Juan-W; García-Carbonero, Rocío (LIPPINCOTT WILLIAMS & WILKINS, 2019-10-01)
    PURPOSE: Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. ...